Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
Major release delivers seamless Ignition SCADA, enterprise-grade security, advanced ML algorithms, and private cloud ...
How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
Recursion Pharmaceuticals RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is expected to report fourth-quarter 2025 results soon. The Zacks Consensus ...
Threat actors abused trusted Trivy distribution channels to inject credential‑stealing malware into CI/CD pipelines worldwide ...
1. Selected dates can't be greater than February 2026. 2. From date can't be greater than To date. 1. Selected dates can't be greater than February 2026. 2. From date can't be greater than To date. 1.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results